INEYE THERAPEUTICS was founded on September 5, 2017, by Marcos Mariz and Paula Ferreira, the company’s CEO and CTO, respectively, two biochemists from the University of Coimbra.
Despite the company’s young age, the two founders have already developed other projects in the area of biomaterials for more than two decades. The idea of creating a start-up came as a need to market the InEye® technology, developed by Marcos during his PhD research.
INEYE THERAPEUTICS contributes to improving people’s quality of life, particularly in the prevention of blindness or visual impairment, by developing innovative medical devices and pharmaceutical products of the highest quality. Our mission is that each person may have “Healthy eyes for a lifetime.”
Marcos developed InEye® technology as his PhD research study in the Chemical Engineering Department of the University of Coimbra.
His core research interests are polymer synthesis for biomedical use and drug delivery systems.
Before founding INEYE THERAPEUTICS, Marcos worked for 14 years in a pharmaceutical company’s R&D center, where he managed an analytical development department.
“The simplicity and versatility of InEye® technology will make it a benchmark on ocular delivery”
Paula is a co-founder of INEYE THERAPEUTICS and a full-time researcher at the Polytechnic University of Coimbra.
She is a Biochemist with a PhD in Chemical Engineering from the University of Coimbra.
Her specialization field is the development of polymeric materials for biomedical applications, namely as drug delivery systems.
“The changes that InEye® will bring to the patient’s daily life will be outstanding.”
Economist from Universidade Católica, with advanced training from institutions such as Kellogg, INSEAD, and Porto Business School. He began his career at KPMG in 1989 and spent over two decades at Galp, including 18 years in executive roles, serving as CFO of Downstream Oil and as President of Galp Açores, Galp Madeira, and Gasinsular. During this period, he also held various leadership and board positions at both national and international levels. In 2019, he led the award-winning project at the Kaizen Global Awards in Galp’s Iberian retail sector. In 2020, he founded Tows&TOOLS Business Consulting, standing out as an entrepreneur. Since 2023 he is also Board Member at Insight Venture SCR.
“At INEYE THERAPEUTICS, we believe that the gift of sight should be naturally preserved throughout life’s journey, especially as we age.”
Nuno has over 29 years of experience in the venture capital industry. As an investment manager, he has been involved in screening investment opportunities, monitoring portfolio companies, mergers and acquisitions, and business structuring across various industries, with a focus on biotechnology, healthcare, and IT industries, particularly in early-stage or seed investments. Currently, Nuno is part of the Therapeutics & Health Tech unit at Portugal Ventures, focusing on generating deal flow and overseeing projects in the MedTech and Digital Health sectors.
Helena Gil is one of the main Portuguese specialists in the biomaterials field and supervised the PhD thesis that led to InEye® development.
She is an Emeritus Professor of the Department of Chemical Engineering at the University of Coimbra. She has published over 200 papers on polymeric biomaterials, 40 of them on drug delivery systems.
“The InEye® technology is excellent due to the stability and biocompatibility of the material.”
Joaquim Murta is the coordinator of the Coimbra Ophthalmology Unit (UOC) and Director of the Ophthalmology Department of the Coimbra Hospital and University Center (CHUC). He is also a full Professor of Ophthalmology at the Faculty of Medicine of the University of Coimbra.
He specialized in the cornea (transplants, external diseases, and refractive surgery) and pediatric ophthalmology.
He has been a member of several Portuguese and International ophthalmology organizations.
Portugal Ventures is a venture capital firm founded in 2012 to support the growth and global expansion of innovative Portuguese startups with high-potential projects.
Portugal Ventures is a leading venture capital investor in life sciences in Portugal and made its first investment in INEYE THERAPEUTICS in 2023 through the Call INNOV-ID initiative.
Insight Venture is a fund management company that invests in innovative Portuguese companies at any stage, with a strong focus on R&D. Backed by a highly experienced team, it provides strategic support, risk analysis, and business structuring to drive growth and profitability.
The project has been awarded with several Portuguese and European prizes:
Attributed to Paula Ferreira as a co-founder and Director of Development at INEYE THERAPEUTICS, Lda.
Attributed to INEYE THERAPEUTICS by the pharmaceutical company Insud Pharma (Madrid, Spain).
Finance and support in developing the business plan for the project “InEye® – Healthy eyes for a lifetime. An ocular insert with drug delivery technology”.
Awarded to Marcos Mariz as PhD student of the University of Coimbra, in the context of an international competition promoted by the European Institute of Innovation & Technology.
Attributed to the project “InEye® – Healthy eyes for a lifetime. An ocular insert with drug delivery technology”.
Awarded by the consortium that includes 10 nuclear partners amongst Entities of Higher Education, Incubators, Applied Research Centers and Science and Technology Parks.
Attributed by a set of Portuguese Institutions. Attributed to the InEye project – Development of an insert for ocular drug release.
Awarded by the Institute for Support to Small and Medium Enterprises and Innovation (IAPMEI) to the InEye project – Development of an insert for ocular drug release – in the scope of the Arrisca C 2016 contest.